Latest Deals
The deal includes an upfront payment of $1bn and an additional $150m tied to regulatory milestones. Credit: Bloomberg / Getty Images
JP Morgan 2025: GSK acquires IDRx in $1.15bn deal
GSK has announced a definitive agreement to acquire IDRx, a US-based biotechnology company specialising in treatments for gastrointestinal cancers, for up to $1.15bn in cash, marking the first deal of the 2025 JP Morgan Healthcare Conference. The deal – which includes an upfront payment of $1bn and an additional $150m tied to regulatory milestones – underscores GSK’s strategy to bolster its oncology portfolio.
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m
Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated mucin-1 (TA-MUC1) antibody, from Glycotope for $132.5m. The gatipotuzumab acquisition builds on a 2017 option agreement and subsequent 2018 licensing deal with Glycotope, the financial terms of which were not disclosed.
Regenxbio and Nippon Shinyaku forge $810m gene therapy deal
Regenxbio has entered into a strategic collaboration worth $810m with Japan-based Nippon Shinyaku to advance gene therapies targeting the rare metabolic disorder mucopolysaccharidosis (MPS). Under the terms of the deal, which centres on two of Regenxbio’s assets – RGX-121 and RGX-111 – Regenxbio will receive $110m upfront and is eligible for up to $700m in development, regulatory, and sales milestones.
Umoja secures $100m to advance CAR-T cell therapy pipeline
Umoja Biopharma has announced the closing of an oversubscribed $100m Series C financing round, which will enable the company to progress its in vivo chimeric antigen receptor (CAR)-T cell therapy pipeline. Double Point Ventures and DCVC Bio jointly led the round, with participation from existing and new investors including ARK Invest, MPM Capital, Cormorant Asset Management, Qiming Venture Partners USA and Alexandria Venture Investments.
